logo
Share SHARE
FONT-SIZE Plus   Neg

AstraZeneca Begins Olaparib Phase III Trial; Reverses $285 Mln Charge

AstraZeneca PLC (AZN.L,AZN: Quote) Wednesday said it enrolled the first patient in the Phase III SOLO, or Study of OLaparib in Ovarian cancer, programme. Olaparib, an innovative oral poly ADP ribose polymerase inhibitor is being investigated for the treatment of BRCA mutated ovarian cancer in SOLO. The clinical development is designed to study the benefit, progression free survival, of olaparib as a maintenance monotherapy in BRCA mutated ovarian cancer patients who are in complete or partial response following platinum-based chemotherapy in the first line setting, SOLO 1, and relapsed setting, SOLO 2.

A pre-tax impairment charge of $285 million, which was incurred in December 2011 after deciding not to progress olaparib into phase III, will be reversed in the third quarter of 2013, following the start of the programme. This reversal will be excluded from the core earning per share, the company said.

The SOLO 1 study is being conducted in collaboration with the Gynecologic Oncology Group and the SOLO 2 study with the European Network of Gynaecological Oncological Trial Groups. Both trials are randomised, double blind, placebo controlled studies that utilise the tablet formulation of olaparib at a dose of 300mg twice daily.

Separately, Myriad Genetics, Inc. (MYGN) said it is expanding its collaboration agreement with AstraZeneca to provide companion diagnostics for the olaparib Phase 3 clinical development program. Pursuant to the agreement, Myriad will build out a new laboratory within its Salt Lake City facility in accordance with U.S. Food and Drug Administration regulations for companion diagnostic devices.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Disney CEO Bob Iger has confirmed that all three films in the upcoming Star Wars trilogy will be out by the end of the decade. With Episode VII set for release later this year, "Star Wars: Episode VIII" will hit theaters in 2017 and that "Star Wars: Episode IX" will arrive in 2019, according to Get... Burger chain Shake Shack Inc. said late Thursday that it has priced its initial public offering of 5 million Class A shares at $21 per share, which is above the previously estimated price range of $17 to $19 per share. The shares are expected to begin trading on the New York Stock Exchange on Friday, January 30 under the ticker symbol "SHAK." Google reported a higher fourth-quarter profit, driven by a 15 percent increase in revenues and one-time gains from the sale of Motorola Mobile business, somewhat offset by stock-based compensation expense and foreign exchange losses. Quarterly earnings and revenue missed Wall Street estimates, as ad revenues came under pressure.
comments powered by Disqus
Follow RTT